Cargando…
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
The investigation of interleukin 1β (IL-1β) in human inflammatory diseases is hampered by the fact that it is virtually undetectable in human plasma. We demonstrate that by administering the anti–human IL-1β antibody canakinumab (ACZ885) to humans, the resulting formation of IL-1β–antibody complexes...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715040/ https://www.ncbi.nlm.nih.gov/pubmed/19364880 http://dx.doi.org/10.1084/jem.20082481 |
_version_ | 1782169726988845056 |
---|---|
author | Lachmann, Helen J. Lowe, Philip Felix, Sandra Daniela Rordorf, Christiane Leslie, Kieron Madhoo, Sheril Wittkowski, Helmut Bek, Stephan Hartmann, Nicole Bosset, Sophie Hawkins, Philip N. Jung, Thomas |
author_facet | Lachmann, Helen J. Lowe, Philip Felix, Sandra Daniela Rordorf, Christiane Leslie, Kieron Madhoo, Sheril Wittkowski, Helmut Bek, Stephan Hartmann, Nicole Bosset, Sophie Hawkins, Philip N. Jung, Thomas |
author_sort | Lachmann, Helen J. |
collection | PubMed |
description | The investigation of interleukin 1β (IL-1β) in human inflammatory diseases is hampered by the fact that it is virtually undetectable in human plasma. We demonstrate that by administering the anti–human IL-1β antibody canakinumab (ACZ885) to humans, the resulting formation of IL-1β–antibody complexes allowed the detection of in vivo–produced IL-1β. A two-compartment mathematical model was generated that predicted a constitutive production rate of 6 ng/d IL-1β in healthy subjects. In contrast, patients with cryopyrin-associated periodic syndromes (CAPS), a rare monogenetic disease driven by uncontrolled caspase-1 activity and IL-1 production, produced a mean of 31 ng/d. Treatment with canakinumab not only induced long-lasting complete clinical response but also reduced the production rate of IL-1β to normal levels within 8 wk of treatment, suggesting that IL-1β production in these patients was mainly IL-1β driven. The model further indicated that IL-1β is the only cytokine driving disease severity and duration of response to canakinumab. A correction for natural IL-1 antagonists was not required to fit the data. Together, the study allowed new insights into the production and regulation of IL-1β in man. It also indicated that CAPS is entirely mediated by IL-1β and that canakinumab treatment restores physiological IL-1β production. |
format | Text |
id | pubmed-2715040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-27150402009-11-11 In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes Lachmann, Helen J. Lowe, Philip Felix, Sandra Daniela Rordorf, Christiane Leslie, Kieron Madhoo, Sheril Wittkowski, Helmut Bek, Stephan Hartmann, Nicole Bosset, Sophie Hawkins, Philip N. Jung, Thomas J Exp Med Brief Definitive Report The investigation of interleukin 1β (IL-1β) in human inflammatory diseases is hampered by the fact that it is virtually undetectable in human plasma. We demonstrate that by administering the anti–human IL-1β antibody canakinumab (ACZ885) to humans, the resulting formation of IL-1β–antibody complexes allowed the detection of in vivo–produced IL-1β. A two-compartment mathematical model was generated that predicted a constitutive production rate of 6 ng/d IL-1β in healthy subjects. In contrast, patients with cryopyrin-associated periodic syndromes (CAPS), a rare monogenetic disease driven by uncontrolled caspase-1 activity and IL-1 production, produced a mean of 31 ng/d. Treatment with canakinumab not only induced long-lasting complete clinical response but also reduced the production rate of IL-1β to normal levels within 8 wk of treatment, suggesting that IL-1β production in these patients was mainly IL-1β driven. The model further indicated that IL-1β is the only cytokine driving disease severity and duration of response to canakinumab. A correction for natural IL-1 antagonists was not required to fit the data. Together, the study allowed new insights into the production and regulation of IL-1β in man. It also indicated that CAPS is entirely mediated by IL-1β and that canakinumab treatment restores physiological IL-1β production. The Rockefeller University Press 2009-05-11 /pmc/articles/PMC2715040/ /pubmed/19364880 http://dx.doi.org/10.1084/jem.20082481 Text en © 2009 Lachmann et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/). |
spellingShingle | Brief Definitive Report Lachmann, Helen J. Lowe, Philip Felix, Sandra Daniela Rordorf, Christiane Leslie, Kieron Madhoo, Sheril Wittkowski, Helmut Bek, Stephan Hartmann, Nicole Bosset, Sophie Hawkins, Philip N. Jung, Thomas In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes |
title | In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes |
title_full | In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes |
title_fullStr | In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes |
title_full_unstemmed | In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes |
title_short | In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes |
title_sort | in vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes |
topic | Brief Definitive Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715040/ https://www.ncbi.nlm.nih.gov/pubmed/19364880 http://dx.doi.org/10.1084/jem.20082481 |
work_keys_str_mv | AT lachmannhelenj invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT lowephilip invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT felixsandradaniela invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT rordorfchristiane invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT lesliekieron invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT madhoosheril invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT wittkowskihelmut invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT bekstephan invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT hartmannnicole invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT bossetsophie invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT hawkinsphilipn invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes AT jungthomas invivoregulationofinterleukin1binpatientswithcryopyrinassociatedperiodicsyndromes |